202 related articles for article (PubMed ID: 29138631)
1. SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors.
Higham CS; Steinberg SM; Dombi E; Perry A; Helman LJ; Schuetze SM; Ludwig JA; Staddon A; Milhem MM; Rushing D; Jones RL; Livingston M; Goldman S; Moertel C; Wagner L; Janhofer D; Annunziata CM; Reinke D; Long L; Viskochil D; Baker L; Widemann BC
Sarcoma; 2017; 2017():8685638. PubMed ID: 29138631
[TBL] [Abstract][Full Text] [Related]
2. Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016).
Widemann BC; Lu Y; Reinke D; Okuno SH; Meyer CF; Cote GM; Chugh R; Milhem MM; Hirbe AC; Kim A; Turpin B; Pressey JG; Dombi E; Jayaprakash N; Helman LJ; Onwudiwe N; Cichowski K; Perentesis JP
Sarcoma; 2019; 2019():7656747. PubMed ID: 31427883
[TBL] [Abstract][Full Text] [Related]
3. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.
Watson KL; Al Sannaa GA; Kivlin CM; Ingram DR; Landers SM; Roland CL; Cormier JN; Hunt KK; Feig BW; Ashleigh Guadagnolo B; Bishop AJ; Wang WL; Slopis JM; McCutcheon IE; Lazar AJ; Torres KE
J Neurosurg; 2017 Jan; 126(1):319-329. PubMed ID: 27035165
[TBL] [Abstract][Full Text] [Related]
4. Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors.
LaFemina J; Qin LX; Moraco NH; Antonescu CR; Fields RC; Crago AM; Brennan MF; Singer S
Ann Surg Oncol; 2013 Jan; 20(1):66-72. PubMed ID: 22878618
[TBL] [Abstract][Full Text] [Related]
5. Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO).
Valentin T; Le Cesne A; Ray-Coquard I; Italiano A; Decanter G; Bompas E; Isambert N; Thariat J; Linassier C; Bertucci F; Bay JO; Bellesoeur A; Penel N; Le Guellec S; Filleron T; Chevreau C
Eur J Cancer; 2016 Mar; 56():77-84. PubMed ID: 26824706
[TBL] [Abstract][Full Text] [Related]
6. Clinical signs of neurofibromatosis impact on the outcome of malignant peripheral nerve sheath tumors.
Lamm W; Schur S; Köstler WJ; Funovics P; Windhager R; Amann G; Panotopoulos J; Pokrajac B; Brodowicz T
Oncology; 2014; 86(2):122-6. PubMed ID: 24480823
[TBL] [Abstract][Full Text] [Related]
7. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH
Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628
[TBL] [Abstract][Full Text] [Related]
8. Identification of serum microRNAs in genome-wide serum microRNA expression profiles as novel noninvasive biomarkers for malignant peripheral nerve sheath tumor diagnosis.
Weng Y; Chen Y; Chen J; Liu Y; Bao T
Med Oncol; 2013 Jun; 30(2):531. PubMed ID: 23483452
[TBL] [Abstract][Full Text] [Related]
9. Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors.
Hagel C; Zils U; Peiper M; Kluwe L; Gotthard S; Friedrich RE; Zurakowski D; von Deimling A; Mautner VF
J Neurooncol; 2007 Apr; 82(2):187-92. PubMed ID: 17111191
[TBL] [Abstract][Full Text] [Related]
10. Malignant peripheral nerve sheath tumours in neurofibromatosis 1.
Evans DG; Baser ME; McGaughran J; Sharif S; Howard E; Moran A
J Med Genet; 2002 May; 39(5):311-4. PubMed ID: 12011145
[TBL] [Abstract][Full Text] [Related]
11. Malignant peripheral nerve sheath tumors (MPNST) in NF1-affected children.
Friedrich RE; Hartmann M; Mautner VF
Anticancer Res; 2007; 27(4A):1957-60. PubMed ID: 17649804
[TBL] [Abstract][Full Text] [Related]
12. NF1
Dodd RD; Lee CL; Overton T; Huang W; Eward WC; Luo L; Ma Y; Ingram DR; Torres KE; Cardona DM; Lazar AJ; Kirsch DG
Cancer Res; 2017 Aug; 77(16):4486-4497. PubMed ID: 28646022
[TBL] [Abstract][Full Text] [Related]
13. Malignant peripheral nerve sheath tumors (MPNST) in neurofibromatosis type 1 (NF1): diagnostic findings on magnetic resonance images and mutation analysis of the NF1 gene.
Friedrich RE; Kluwe L; Fünsterer C; Mautner VF
Anticancer Res; 2005; 25(3A):1699-702. PubMed ID: 16033085
[TBL] [Abstract][Full Text] [Related]
14. Metastatic Malignant Peripheral Nerve Sheath Tumor With NF1 Successfully Treated With 'Gradual Subtraction' ICE Chemotherapy.
Wang Y; Katagiri H; Murata H; Wasa J; Miyagi M; Kakuda Y; Takahashi M
Anticancer Res; 2020 Mar; 40(3):1619-1624. PubMed ID: 32132065
[TBL] [Abstract][Full Text] [Related]
15. Neurofibromatosis-associated malignant peripheral nerve sheath tumors in children have a worse prognosis: A nationwide cohort study.
Martin E; Coert JH; Flucke UE; Slooff WM; van de Sande MAJ; van Noesel MM; Grünhagen DJ; Wijnen MHWA; Verhoef C
Pediatr Blood Cancer; 2020 Apr; 67(4):e28138. PubMed ID: 31889416
[TBL] [Abstract][Full Text] [Related]
16. Early outcomes for malignant peripheral nerve sheath tumor treated with chemotherapy.
Moretti VM; Crawford EA; Staddon AP; Lackman RD; Ogilvie CM
Am J Clin Oncol; 2011 Aug; 34(4):417-21. PubMed ID: 20838322
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor, basic fibroblast growth factor and epithelial growth factor receptor in peripheral nerve sheath tumors of neurofibromatosis type 1.
Friedrich RE; Beer C; Glatzel M; Hagel C
Anticancer Res; 2015 Jan; 35(1):137-44. PubMed ID: 25550544
[TBL] [Abstract][Full Text] [Related]
18. Systemic Options for Malignant Peripheral Nerve Sheath Tumors.
Hassan A; Pestana RC; Parkes A
Curr Treat Options Oncol; 2021 Feb; 22(4):33. PubMed ID: 33641042
[TBL] [Abstract][Full Text] [Related]
19. Outcome and prognostic factors in pediatric malignant peripheral nerve sheath tumors: An analysis of the European Pediatric Soft Tissue Sarcoma Group (EpSSG) NRSTS-2005 prospective study.
van Noesel MM; Orbach D; Brennan B; Kelsey A; Zanetti I; de Salvo GL; Gaze MN; Craigie RJ; McHugh K; Francotte N; Collini P; Bisogno G; Casanova M; Ferrari A
Pediatr Blood Cancer; 2019 Oct; 66(10):e27833. PubMed ID: 31241238
[TBL] [Abstract][Full Text] [Related]
20. Aberrant ATRX protein expression is associated with poor overall survival in NF1-MPNST.
Lu HC; Eulo V; Apicelli AJ; Pekmezci M; Tao Y; Luo J; Hirbe AC; Dahiya S
Oncotarget; 2018 May; 9(33):23018-23028. PubMed ID: 29796169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
